Loading
Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.
Mark Litzow is Professor of Medicine at Mayo Clinic, Chair of the ECOG-ACRIN Leukemia Committee and Study Chair of E1910. A haematologist specialising in acute lymphoblastic leukaemia, immunotherapy and transplant, he chaired ECOG-ACRIN E1910, the trial that put blinatumomab consolidation into frontline treatment for adults in MRD-negative remission and led to a 2024 label change. His papers report blinatumomab for MRD-negative acute lymphoblastic leukaemia in adults in the New England Journal of Medicine and allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukaemia in Blood. His work centres on CD19 and CD3 directed therapy in B-ALL.
| Title | Journal | Year |
|---|---|---|
| Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults | New England Journal of Medicine | 2024 |
| Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia | Blood | 2010 |
Shares ECOG-ACRIN E1910, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19.
Shares ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD3, CD19.